Gil C / Shutterstock.com
The Indian Patent Office has rejected Johnson & Johnson subsidiary Janssen Pharmaceutica’s application to patent its HIV drug Edurant (rilpivirine), according to a report by The Financial Express.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Indian Patent office, Janssen, J&J, Cipla, Edurant